Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
about
Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminansEpidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Practical aspects of treatment with drotrecogin alfa (activated)Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency MedicineHuman protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patientsIntracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy?Year in review 2005: Critical Care - resource management.Diagnosis and management of meningococcal disease: the need for centralized care.ICU 2020: five interventions to revolutionize quality of care in the ICU.Sepsis-induced purpura fulminans caused by Pasteurella multocida.Purpura fulminans in meningococcal septicaemia in an adult: a case report.Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study.[Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE)].Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis.
P2860
Q28296136-200F09DE-2A70-4BB3-9968-9CD4CC71AD8AQ30431534-9A7ABEC0-1A90-4D21-9399-66439C6BF62AQ33378616-6C0DAC66-6683-497F-889E-5F90B7DBA4A0Q33974292-8FBA1605-E07D-4CB7-8E67-A288EB5D344FQ34153375-DA4494EF-8A52-4E69-A0F3-9584753B79A2Q34428572-8AE35391-EBDD-4E03-B04F-D239C4729716Q36526015-46F8D75A-102E-4E2D-84DA-275F54A3428BQ36711470-94435535-B357-424E-A612-DA854DAA8116Q37983541-13197268-FC27-40D9-A185-A92DC39A4F84Q38189777-986C6E0D-C572-40D5-9009-366A15EAC6BDQ38640760-EF908AD8-BB5D-4574-8DA2-DA9FBE36764BQ40171729-4D3A6057-5890-4254-A30F-4BE90135D014Q41687756-E162E297-FB8C-45FB-8B1F-EC9E69A3A5C3Q54576419-20B0BF80-6B6A-46DA-BC5F-18840C43917C
P2860
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Drotrecogin alfa (activated) i ...... led in recent clinical studies
@nl
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@ast
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@en
type
label
Drotrecogin alfa (activated) i ...... led in recent clinical studies
@nl
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@ast
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@en
prefLabel
Drotrecogin alfa (activated) i ...... led in recent clinical studies
@nl
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@ast
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@en
P2093
P2860
P356
P1433
P1476
Drotrecogin alfa (activated) i ...... ed in recent clinical studies.
@en
P2093
Carol L Mitchell
Demetrios J Kutsogiannis
Joan E Bailey
Jonathan M Janes
R T Noel Gibney
S Betty Yan
Samiha Sarwat
Simon Nadel
Stephen M Shinall
Virginia L Wyss
P2860
P2888
P304
P356
10.1186/CC3538
P407
P577
2005-05-17T00:00:00Z
P5875
P6179
1001551420